$ダイナバクス テクノロジーズ(DVAX.US)$Reuters· 1 min ago Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
Dynavax Technologies' long-term performance remains strong despite a recent 8.6% pullback. The company's profit growth is commendable, and its 15% annual gain, though below market return, surpasses its 5-year average, suggesting a successful strategy attracting new investors.
📈 Stock #1 - SoFi 📈 Dr. Stock is bullish on SoFi, considering it a fundamental long-term play with potential growth. He's eagerly awaiting Q2 earnings to see if they stay on track to achieve profitability by Q4 2023. Dr. Stock talks about possible price drops in the short term, which could create great buying opportunities for the long term. He also discusses potential resistance levels and trade plays as the stock approaches key price points. 🚗 Stock #2 - Tes...
Welcome back to the channel! In this video, Dr. Stock, a doctor of Education, will be discussing various stocks, including some he recently mentioned in his previous videos. He provides updates on Sofi and Tesla as well. Dr. Stock focuses on stocks that are currently not hyped up, which makes their technical analysis more predictable compared to heavily hyped stocks like pure play A.I. stocks. To analyze these stocks, Dr. Stock uses Moomoo, a platform where you can get up...
Let's start with C3.ai. Recently, we witnessed an interesting pattern where the stock showed significant movement. In a previous video, I mentioned that this stock was expected to experience a substantial move, although the direction was uncertain. This presented an opportunity for options plays like the long straddle or long strangle to take advantage of the expected volatility. If you are unfamiliar with options, there are alternative ways to play volatility. However, it's...
ダイナバクス テクノロジーズに関するコメント
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
📣 4 PDUFAs upcoming in May:
$ダイナバクス テクノロジーズ(DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$アセンディス・ファーマ(ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$ブリストル マイヤーズ スクイブ(BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4ファーマシューティカルズ(XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
$ファイザー(PFE.US)$ $ダイナバクス テクノロジーズ(DVAX.US)$ $サンドストーム・ゴールド(SAND.US)$ $ブリストル マイヤーズ スクイブ(BMY.US)$ $SPDR S&P Biotech ETF(XBI.US)$
Dr. Stock is bullish on SoFi, considering it a fundamental long-term play with potential growth. He's eagerly awaiting Q2 earnings to see if they stay on track to achieve profitability by Q4 2023. Dr. Stock talks about possible price drops in the short term, which could create great buying opportunities for the long term. He also discusses potential resistance levels and trade plays as the stock approaches key price points.
🚗 Stock #2 - Tes...
To analyze these stocks, Dr. Stock uses Moomoo, a platform where you can get up...
If you are unfamiliar with options, there are alternative ways to play volatility. However, it's...
- Stock recent runner breaking higher. Back above IPO price. Adding above $15.50
$ダイナバクス テクノロジーズ(DVAX.US)$
- Stock in a nice uptrend from recent news and continues to hold levels. Looking for breakout higher above $13
$BPプルドー・ベイ・ロイヤルティ・トラスト(BPT.US)$
- Stock breaking higher with rise in oil prices. Almost hit $26. Looking for another move higher.
$エンベラ コーポレーション(ELA.US)$
- stock breaking out. Not seeing any specific news. On watch.
$エナジー フォーカス(EFOI.US)$
...
まだコメントはありません